166 related articles for article (PubMed ID: 22323435)
1. Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo.
Heath CH; Sorace A; Knowles J; Rosenthal E; Hoyt K
Otolaryngol Head Neck Surg; 2012 Jun; 146(6):938-45. PubMed ID: 22323435
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma.
Knowles JA; Heath CH; Saini R; Umphrey H; Warram J; Hoyt K; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2012 Jul; 138(7):662-8. PubMed ID: 22801891
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice.
Wang Y; Dong L; Bi Q; Li X; Wu D; Ge X; Zhang X; Fu J; Zhang C; Wang C; Li S
Target Oncol; 2010 Dec; 5(4):237-43. PubMed ID: 21086056
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.
Sorace AG; Korb M; Warram JM; Umphrey H; Zinn KR; Rosenthal E; Hoyt K
Ultrasound Med Biol; 2014 Apr; 40(4):755-64. PubMed ID: 24412168
[TBL] [Abstract][Full Text] [Related]
7. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
Clémenson C; Jouannot E; Merino-Trigo A; Rubin-Carrez C; Deutsch E
Invest New Drugs; 2013 Apr; 31(2):273-84. PubMed ID: 22810221
[TBL] [Abstract][Full Text] [Related]
8. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.
Dias JD; Guse K; Nokisalmi P; Eriksson M; Chen DT; Diaconu I; Tenhunen M; Liikanen I; Grénman R; Savontaus M; Pesonen S; Cerullo V; Hemminki A
Eur J Cancer; 2010 Feb; 46(3):625-35. PubMed ID: 20006487
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma.
Knowles JA; Golden B; Yan L; Carroll WR; Helman EE; Rosenthal EL
Laryngoscope; 2011 Nov; 121(11):2359-65. PubMed ID: 22020886
[TBL] [Abstract][Full Text] [Related]
10. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma.
Ley J; Mehan P; Wildes TM; Thorstad W; Gay HA; Michel L; Nussenbaum B; Trinkaus K; Adkins D
Oncology; 2013; 85(5):290-6. PubMed ID: 24217231
[TBL] [Abstract][Full Text] [Related]
12. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
16. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
Schmitt NC; Trivedi S; Ferris RL
Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
[TBL] [Abstract][Full Text] [Related]
17. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of Cetuximab and photodynamic therapy in SNU-1041 squamous cancer cell line.
Kim SG; Hong JW; Boo SH; Kim MG; Lee KD; Ahn JC; Hwang HJ; Shin JI; Lee SJ; Oh JK; Chung PS
Oncol Rep; 2009 Oct; 22(4):701-8. PubMed ID: 19724846
[TBL] [Abstract][Full Text] [Related]
19. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
[TBL] [Abstract][Full Text] [Related]
20. Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?
Wagenblast J; Baghi M; Mörtel S; Hirth D; Thron L; Arnoldner C; Gstöttner W; May A; Hambek M
Oncol Rep; 2009 Jul; 22(1):171-6. PubMed ID: 19513520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]